New Speakers from Abbvie, GSK, Scripps Research and Engitix Therapeutics Join 3D Cell Culture Virtual Conference in 4 Weeks
SMi Group reports: new speakers from Abbvie, GSK, Scripps Research and Engitix Therapeutics join the 5th Annual 3D Cell Culture Conference in February 2022.
London, United Kingdom, January 16, 2022 --(PR.com)-- Only four weeks to go until the 5th Annual 3D Cell Culture will now take place as a ‘Virtual Conference’ with online access only on 9th and 10th February 2022.
Over the past few years, 3D Cell Culture has gained momentum within the pharmaceutical industry due to the benefits that this model offers for in vitro applications patient-derived tissues, drug discovery, predictivity and validation, and safety and toxicity.
3D Cell Culture technology promises to offer increased translatability in models and reduce the costly rates of drug attrition in the discovery process -- heralding the next major advance in the discovery of pharmaceuticals.
Interested parties can register for the virtual conference at www.3D-cellculture.com/PR3.
SMi Group are delighted to welcome new speakers from leading pharmaceutical companies; Abbvie, GSK, Scripps Research and Engitix Therapeutics who are speaking live for the first time at this conference:
Terry Van Vleet, Investigative Toxicology and Pathology, AbbVie will be presenting on Application/Characterization of Organ-on-a-Chip Platforms from Preclinical Species in Drug Safety and ADME Testing, covering:
• The need and applications for animal cell-based chips in safety assessment of drugs
• Challenges and barriers to building chips from animal cells
• An approach to building animal cell chips, the outcome of that effort, and lessons learned
• Need for improved value compared to spheroids for increased cost/time
BanuPriya Sridharan, Investigator Organoid and Cell Body, GSK will be presenting on
HTS Considerations For Implementing Complex Co-Culture Models As Secondary Screening Tools, which focuses on:
• Traditional HTS utilizes tumor cells in two-dimensional format that fail to recapitulate the complex tumor microenvironment (TME) morphology and do not translate well to in vivo and clinical outcomes
• We developed a versatile triculture model of NSCLC that incorporates cancer associated cells such as normal lung fibroblasts and normal bronchiolar epithelial cells, and, components of the extracellular matrix (ECM), in the context of developing robust, scalable and functional assays
• To assess cytotoxicity, tumor cell viability was determined via cell Titer-Glo or inherent GFP expression in the tumor cells by high content analysis (HCA)
• This allowed the screening of PARP inhibitors across drug sensitive and resistant cell lines in traditional versus triculture platforms
Luca Frenguelli, Senior Scientist, Engitix Therapeutics is speaking on Human tissue-specific extracellular matrix 3D models: a unique approach for novel target identification and drug screening, which covers:
• Development of decellularized tissue-specific extracellular matrix (ECM) scaffolds
• Advantages of using ECM-based 3D models compared to twodimensional models on plastic
• Use of tissue-specific ECM hydrogels as a scalable and reproducible model to mimicking human disease, an overview
Louis Scampavia,Scientific Director, Sr, Scripps Research will be discussing 3D uHTS Models for Chemo Response Profiling of Cancer which will focus on:
• 3D Pancreas and Brain Cancer Modeling
• 3D Technology and HTS Protocol
• Primary cell isolation from patients
• Screening the NCI Oncology Drug Set
• Dose Response results
• Drug Gene Network Analysis
• Synergy studies
To find out more about our speakers, visit the download section and download the ‘speaker biographies’ at www.3D-cellculture.com/PR3.
For sponsorship enquiries, contact Daniele Moreschi, Sales Director on +44 (0)20 7827 6164 or dmoreschi@smi-online.co.uk
For media enquiries and/or press passes, contact Simi Sapal, Head of Marketing on +44 (0) 20 7827 6162 or ssapal@smi-online.co.uk
SMi’s 5th Annual 3D Cell Culture Virtual Conference
Workshops: 8 February 2022
Conference: 9-10 February 2022
London, UK
http://www.3D-cellculture.com/PR3
#SMi3DCellCulture
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Over the past few years, 3D Cell Culture has gained momentum within the pharmaceutical industry due to the benefits that this model offers for in vitro applications patient-derived tissues, drug discovery, predictivity and validation, and safety and toxicity.
3D Cell Culture technology promises to offer increased translatability in models and reduce the costly rates of drug attrition in the discovery process -- heralding the next major advance in the discovery of pharmaceuticals.
Interested parties can register for the virtual conference at www.3D-cellculture.com/PR3.
SMi Group are delighted to welcome new speakers from leading pharmaceutical companies; Abbvie, GSK, Scripps Research and Engitix Therapeutics who are speaking live for the first time at this conference:
Terry Van Vleet, Investigative Toxicology and Pathology, AbbVie will be presenting on Application/Characterization of Organ-on-a-Chip Platforms from Preclinical Species in Drug Safety and ADME Testing, covering:
• The need and applications for animal cell-based chips in safety assessment of drugs
• Challenges and barriers to building chips from animal cells
• An approach to building animal cell chips, the outcome of that effort, and lessons learned
• Need for improved value compared to spheroids for increased cost/time
BanuPriya Sridharan, Investigator Organoid and Cell Body, GSK will be presenting on
HTS Considerations For Implementing Complex Co-Culture Models As Secondary Screening Tools, which focuses on:
• Traditional HTS utilizes tumor cells in two-dimensional format that fail to recapitulate the complex tumor microenvironment (TME) morphology and do not translate well to in vivo and clinical outcomes
• We developed a versatile triculture model of NSCLC that incorporates cancer associated cells such as normal lung fibroblasts and normal bronchiolar epithelial cells, and, components of the extracellular matrix (ECM), in the context of developing robust, scalable and functional assays
• To assess cytotoxicity, tumor cell viability was determined via cell Titer-Glo or inherent GFP expression in the tumor cells by high content analysis (HCA)
• This allowed the screening of PARP inhibitors across drug sensitive and resistant cell lines in traditional versus triculture platforms
Luca Frenguelli, Senior Scientist, Engitix Therapeutics is speaking on Human tissue-specific extracellular matrix 3D models: a unique approach for novel target identification and drug screening, which covers:
• Development of decellularized tissue-specific extracellular matrix (ECM) scaffolds
• Advantages of using ECM-based 3D models compared to twodimensional models on plastic
• Use of tissue-specific ECM hydrogels as a scalable and reproducible model to mimicking human disease, an overview
Louis Scampavia,Scientific Director, Sr, Scripps Research will be discussing 3D uHTS Models for Chemo Response Profiling of Cancer which will focus on:
• 3D Pancreas and Brain Cancer Modeling
• 3D Technology and HTS Protocol
• Primary cell isolation from patients
• Screening the NCI Oncology Drug Set
• Dose Response results
• Drug Gene Network Analysis
• Synergy studies
To find out more about our speakers, visit the download section and download the ‘speaker biographies’ at www.3D-cellculture.com/PR3.
For sponsorship enquiries, contact Daniele Moreschi, Sales Director on +44 (0)20 7827 6164 or dmoreschi@smi-online.co.uk
For media enquiries and/or press passes, contact Simi Sapal, Head of Marketing on +44 (0) 20 7827 6162 or ssapal@smi-online.co.uk
SMi’s 5th Annual 3D Cell Culture Virtual Conference
Workshops: 8 February 2022
Conference: 9-10 February 2022
London, UK
http://www.3D-cellculture.com/PR3
#SMi3DCellCulture
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Contact
SMi Group
Simi Sapal
(0) 20 7827 6162
http://www.3D-cellculture.com/PR3
Simi Sapal
(0) 20 7827 6162
http://www.3D-cellculture.com/PR3
Contact
Categories